The Big Idea
Tatem describes peptides as highly specific chemical keys that target cellular receptors, offering more precise therapeutic interventions than broad-acting small molecule drugs. He argues that while GLP-1 agonists and healing peptides show therapeutic potential for metabolic dysfunction and recovery, regulatory restrictions and lack of patentability create economic barriers to widespread clinical access and standardized research.
